Q3 2021 Investor Relations Results slide image

Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Harry Kirsch Chief Financial Officer Financial review and 2021 guidance 37 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation